CoChat

Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1

Open access
Payne, Jonathan M., Barton, Belinda, Ullrich, Nicole J., Cantor, Alan, Hearps, Stephen J.C., Cutter, Gary, Rosser, Tena, Walsh, Karin S., Gioia, Gerard A., Wolters, Pamela L., Tonsgard, James, Schorry, Elizabeth, Viskochil, David, Klesse, Laura, Fisher, Michael, Gutmann, David H., Silva, Alcino J., Hunter, Scott J., Rey-Casserly, Celiane, Cantor, Nancy L., Byars, Anna W., Stavinoha, Peter L., Ackerson, Joseph D., Armstrong, Carol L., Isenberg, Jill, O'Neil, Sharon H., Packer, Roger J., Korf, Bruce, Acosta, Maria T., North, Kathryn N., For the NF Clinical Trials Consortium, NF Clinical Trials Consortium, Allen, Jeffery, Reddy, Alyssa, Avery, Robert, Flanigan, Cynthia · 2016 · Neurology
Cited by 102

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess the efficacy of lovastatin on visuospatial learning and attention for treating cognitive and behavioral deficits in children with neurofibromatosis type 1 (NF1). METHODS: A multicenter, international, randomized, double-blind, placebo-controlled trial was conducted between July 2009 and May 2014 as part of the NF Clinical Trials Consortium. Children with NF1 aged 8-15 years were screened for visuospatial learning or attention deficits (n = 272); 146 children demonstrated deficits at baseline and were randomly assigned to lovastatin (n = 74; 40 mg/d) or placebo (n = 70). Treatment was administered once daily for 16 weeks. Primary outcomes were total errors on the Cambridge Neuropsychological Test Automated Battery Paired Associate Learning task (visuospatial learning) and the Score subtest from the Test of Everyday Attention for Children (sustained attention). Secondary outcomes measured executive function, attention, visuospatial skills, behavior, and quality of life. Primary analyses were performed on the intention-to-treat population. RESULTS: Lovastatin had no significant effect on primary outcomes after 16 weeks of treatment: visuospatial learning (Cohen d = -0.15, 95% confidence interval -0.47 to 0.18) or sustained attention (Cohen d = 0.19, 95% confidence interval -0.14 to 0.53). Lovastatin was well tolerated, with no increase in reported adverse events compared to placebo. CONCLUSIONS: Lovastatin administered once daily for 16 weeks did not improve visuospatial learning or attention in children with NF1 and is not recommended for amelioration of cognitive deficits in this population. CLINICALTRIALSGOV IDENTIFIER: This study was registered at ClinicalTrials.gov (NCT00853580) and Australian New Zealand Clinical Trials Registry (ACTRN12607000560493). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for children with NF1, lovastatin does not improve visuospatial learning or attention deficits.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000003435

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 102

Metadata

Authors
Payne, J. M., Barton, B., Ullrich, N. J., Cantor, A., Hearps, S. J. C., Cutter, G., Rosser, T., Walsh, K. S., Gioia, G. A., Wolters, P. L., Tonsgard, J., Schorry, E., Viskochil, D., Klesse, L., Fisher, M., Gutmann, D. H., Silva, A. J., Hunter, S. J., Rey-Casserly, C., Cantor, N. L., Byars, A. W., Stavinoha, P. L., Ackerson, J. D., Armstrong, C. L., Isenberg, J., O'Neil, S. H., Packer, R. J., Korf, B., Acosta, M. T., North, K. N., For the NF Clinical Trials Consortium, NF Clinical Trials Consortium, Allen, J., Reddy, A., Avery, R., & Flanigan, C.
Venue
Neurology
Published
2016-12-13
Volume
87
Issue
24
Pages
2575-2584
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2550279928
Cited by
102
References
5
FWCI
6.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. https://app.cochat.ai/papers/10.1212/wnl.0000000000003435
The paper
Payne, J. M., Barton, B., Ullrich, N. J., Cantor, A., Hearps, S. J. C., Cutter, G., Rosser, T., Walsh, K. S., Gioia, G. A., Wolters, P. L., Tonsgard, J., Schorry, E., Viskochil, D., Klesse, L., Fisher, M., Gutmann, D. H., Silva, A. J., Hunter, S. J., Rey-Casserly, C., . . . Flanigan, C. (2016). Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. https://doi.org/10.1212/wnl.0000000000003435

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.